The presence of MYC translocation and high MYC mRNA expression have recently been associated with poor OS in patients with DLBCL treated with R-CHOP, raising questions about optimal management of ...

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 70+ ...

Kura Oncology and Kyowa Kirin announce FDA acceptance and Priority Review of New Drug Application for ziftomenib in adults with relapsed or refractory NPM1-mutant AML. News release. Kura Oncology.

The company noted that the NDA is based on results from the Phase 2 KOMET-001 registrational trial in R/R NPM1-mutant (NPM1-m) AML. The KOMET-001 trial achieved its primary endpoint of complete ...

The NPM1 mutation affects about 30% of all AML patients. In almost half of those patients, relapse or resistance to standard treatments occurs within a year of treatment.

– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 ...

About NPM1 -Mutant AML . AML is the most common acute leukemia in adults and begins when the bone marrow makes abnormal myeloblasts (white blood cells), red blood cells or platelets.

Led by Ryan Flynn, MD, PhD, assistant professor of stem cell and regenerative biology at Harvard Medical School (HMS), the study identified one RNA-binding protein on the cell surface, NPM1, as a ...

Targeting the NPM1 protein. AML, a rapidly progressive blood cancer, has been difficult to target therapeutically because many of its driving pathways are also essential for non-cancerous cells, ...

When researchers inhibited RBM42 in mice, the cells kept producing Myc mRNA, but not Myc protein. “Think about having a lot of Legos,” Ruggero said. “You put them all together.

Ziftomenib targets relapsed/refractory AML with NPM1 mutations, a condition with high relapse rates and poor survival outcomes. The drug has received breakthrough therapy, fast track, and orphan drug ...

JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.